#OncTwitter hashtag - Bluesky

FMT in combination with ICI-based therapy shows promise in multiple cancers Three trials point to the potential of fecal microbiota transplantation to enhance the efficacy of immune checkpoint inhibitor-based therapy in people with cancer.

1 month ago

#MedNews - Three trials point to the potential of fecal microbiota transplantation to enhance the efficacy of ICI-based therapy in people with #cancer.

Full story 👉 buff.ly/A37tGMc

#OncTwitter

0 0 0 0

University Hospital Department of Medicine

1 month ago

📝Access the full Small Cell Lung Cancer Quiz here: bit.ly/SCLC_ONCO_IQ_X

🧠This week’s ONCO-IQ Quiz challenge is on Small Cell Lung Cancer. Comment the right answer below.👇🏻

#SCLC #SmallCellLungCancer #LungCancer #MedTwitter #OncTwitter #MedEd #ONCOIQ

0 0 0 0

@uhcwrudom.bsky.social

1 month ago

Congrats to Dr. Oladayo Oyebanji for winning an ASH Abstract Achievement Award! His study of 13k+ patients shows that Medicaid expansion significantly improved survival rates for CML patients across all demographics.

Read his latest in @JAMANetworkOpen!

#MedEd #HealthEquity #OncTwitter

2 0 0 0

American Society of Clinical Oncology

@ascocancer.bsky.social

2 months ago

Attention early-career oncologists! There's still time to apply for the @ConquerCancerFd YIA in Primary Brain Tumors. This mentored award supports your transition from fellowship to faculty.

Apply by March 12th: https://bit.ly/4rhR8pn
#OncTwitter #ResearchFunding

2 0 0 0

American Society of Clinical Oncology

@ascocancer.bsky.social

2 months ago

Abstracts for #GI26 now available! Discover emerging treatment modalities, the latest clinical trial results, advances in precision medicine, and more—all in the field of gastrointestinal cancers. #gicsm #OncTwitter

View the abstracts: brnw.ch/21wYQVs

1 1 0 0

Fumiko Ladd Chino, MD FASCO

@fumikochino.bsky.social

4 months ago

A woman in a purple HCWvsHunger shirt at her work desk

#ThreeGoodThings:
1️⃣ 4/4 #radonc in my family donated this year to #HCWvsHunger for our #oncTwitter team
2️⃣ my 🍎order arrived just in time for our last day
3️⃣ honored to run #DiagnoseAndTreats with Drs @kemimdrad.bsky.social @tmprowell.bsky.social @rovingatuscap.bsky.social
@01sth02.bsky.social 🙏

10 2 0 0

A clinical report and analysis of metachronous multiple primary cancers occurred in four sites A rare occurrence of four primary malignancies – bilateral breast cancer, ovarian cancer, and undifferentiated high-grade pleomorphic sarcoma. Could the patient have a hereditary cancer syndrome?

4 months ago

#MedCase - A rare occurrence of four primary malignancies – bilateral breast cancer, ovarian cancer, and undifferentiated high-grade pleomorphic sarcoma.

Could the patient have a hereditary cancer syndrome?

👉 buff.ly/zHygeIJ

#OncTwitter

0 0 0 0

4 months ago

25 years since the first phase 2 trial for the first #TKI, we reflect on this key breakthrough in the treatment of #CML with Dr. Jorge Cortes, who has been involved in the development of TKIs since the early days.

Listen now 🔉 buff.ly/afBarZg

#OncTwitter

1 1 0 0

@tumorboardtuesday.bsky.social

5 months ago

🎬That’s a wrap from #ESMO25

Incredible few days connecting with oncology professionals, pharma leaders & our amazing
ONCOassist community.

Thank you for the energy, ideas & feedback. Can’t wait for ESMO 2026! 📷

#ESMO2025 #Oncology #OncoAlert #OncTwitter

0 0 0 0

Tumor Board Tuesday

5 months ago

15/18 #TumorBoardTuesday
⏭️ Moving on to Case 3…

#TumorBoardTuesday #OncTwitter Case 3
👩‍🦳 67 y.o. postmenopausal female
💉 Metastatic HR+, “HER2 low” BC to bone, liver
💊 Progressed on 1L CDK4/6i + ET within 4 months of starting therapy
🧪 No BRCA mutations

0 0 1 0

Margaret Gatti-Mays, MD MPH

@drgattimays.bsky.social

5 months ago

15/18 #TumorBoardTuesday
⏭️ Moving on to Case 3…

#TumorBoardTuesday #OncTwitter Case 3
👩‍🦳 67 y.o. postmenopausal female
💉 Metastatic HR+, “HER2 low” BC to bone, liver
💊 Progressed on 1L CDK4/6i + ET within 4 months of starting therapy
🧪 No BRCA mutations

0 0 2 0

Tumor Board Tuesday

@tumorboardtuesday.bsky.social

5 months ago

9/18 #TumorBoardTuesday
⏭️ Case 2

#TumorBoardTuesday #OncTwitter Case 2
👩‍🦳 62 y.o. postmenopausal female
💉 mBC to the🫁, ER 70%, PR 85%, HER2⛔[IHC 1] 🩻 confirmed⬆️Dz on 1L ribo/letrozole at C7
🏃‍♀️ ECOG PS 1. No co-morbidities.
⛔ Normal vital signs, labs
🩸Liquid Biopsy shows ESR1 mutation, TMB-High

1 1 2 0

Margaret Gatti-Mays, MD MPH

@drgattimays.bsky.social

5 months ago

9/18 #TumorBoardTuesday
⏭️ Moving on to Case 2…

#TumorBoardTuesday #OncTwitter Case 2
👩‍🦳 62 y.o. postmeno female
💉 mBC to the lungs, ER 70%, PR 85%, HER2 neg [IHC 1] with progression on 1L ribociclib/letrozole at C7.
🏃‍♀️ ECOG PS1. No co-morbidities.
⛔ Nml VS, labs
🩸Liquid Biopsy: ESR1mut, TMB-High

0 0 0 0

Margaret Gatti-Mays, MD MPH

@drgattimays.bsky.social

5 months ago

1/18 #TumorBoardTuesday #OncTwitter Case 1
👩‍🦳 57 y.o. postmenopausal female
📋 Well controlled diabetes (A1C = 5.8)
🏃‍♀️ ECOG PS 0
💉 Metastatic breast cancer to the bones, liver, ER100%, PR95%, HER2 neg [IHC 0] with scan confirmed progression on 1L ribociclib/letrozole Cyc 47 in bones.
⛔ Normal labs,VS

0 0 0 0

5 months ago

🌟 Day 4 was exciting and full of new connections at #ESMO25!

Thanks to everyone who visited the ONCOassist booth 🤝

Looking forward to seeing you all on the final day of ESMO 2025.

#OncoAlert #ONCOassist #OncEd #myESMOStory #OncTwitter #ESMO2025 #Berlin #Germany

0 0 0 0

Medthority

@medthority.bsky.social

5 months ago

“PARPi may be approved in the mHSPC setting in the near future.” – @neerajagarwal.bsky.social at #ESMO25.

Ongoing trials could expand the reach of precision therapy beyond mCRPC

#ProstateCancer #Oncology #OncTwitter #MedEd #MedX #mPC #mHSPC

1 1 0 0

5 months ago

✨ Day 3 at #ESMO25 had been incredible!

Thanks to everyone who visited the ONCOassist booth.

Looking forward to seeing everyone on Day 4.

#ONCOassist #OncoAlert #OncEd #myESMOStory #OncTwitter #ESMO2025 #Berlin #Germany

0 0 0 0

5 months ago

✨ Day 2 at #ESMO2025 was all about exciting conversations and great energy.

We’re thrilled to meet so many oncology professionals — join us again on Day 3! 🤝

#ONCOnews #OncoAlert #OncEd #myESMOStory #OncTwitter #ESMO25 #Berlin #Germany

1 0 0 0

5 months ago

✨Inspiring conversations & new connections at #ESMO25! A big thank you to everyone who visited our booth.

Excited for more learning, networking, and innovation on Day 2!

#ONCOassist #OncoAlert #myESMOStory #ESMO2025 #OncologyUpdates #MedicalConference #Berlin #Germany #OncTwitter

0 0 0 0

#ONCOassist #OncoAlert #ESMO25 #Oncology #MedTech #myESMOStory #ESMO2025 #OncTwitter

5 months ago

0 0 0 0

International Neuroendocrine Cancer Alliance (INCA)

5 months ago

ONCOassist

⬇️ If you’re an HCP, download our app now : bit.ly/download_ONC...

#ONCOassist #OncoAlert #Oncology #DigitalHealth #HealthTech #ClinicalTools #OncologyApp #CancerCare #Oncologist #MedicalApps #OncologyCommunity #HealthCareProfessionals #OncTwitter

0 0 0 0

@inca-netcancerday.bsky.social

7 months ago

INCA’s researcher insights video collection brings you the newest updates in NEN research—straight from the experts.
📱Watch here: incalliance.org/researcher-i...
🌍Available in English with captions in French, German, Italian, Portuguese and Spanish.
#LetsTalkAboutNETs #OncTwitter

0 1 0 0

@targetedonc.bsky.social

8 months ago

FDA Issues Complete Response Letter for Glofitamab in R/R DLBCL Combination Therapy FDA issues a complete response letter for glofitamab's second-line DLBCL indication, highlighting ongoing scrutiny in oncology therapy approvals.

FDA issues CRL for glofitamab + GemOx in 2L R/R DLBCL, citing limited US patient enrollment in STARGLO study. Glofitamab retains accelerated approval as monotherapy in later lines. Important regulatory update for clinicians. #Lymphoma #DLBCL #OncTwitter #FDA www.targetedonc.com/view/fda-iss...

0 0 1 0